-$0.61 Earnings Per Share Expected for Heron Therapeutics Inc (NASDAQ:HRTX) This Quarter

Brokerages expect Heron Therapeutics Inc (NASDAQ:HRTX) to post earnings per share (EPS) of ($0.61) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings. The lowest EPS estimate is ($0.65) and the highest is ($0.56). Heron Therapeutics reported earnings per share of ($0.63) during the same quarter last year, which indicates a positive year over year growth rate of 3.2%. The firm is scheduled to announce its next earnings results on Monday, August 3rd.

On average, analysts expect that Heron Therapeutics will report full-year earnings of ($2.33) per share for the current fiscal year, with EPS estimates ranging from ($2.77) to ($1.41). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.92) per share, with EPS estimates ranging from ($2.00) to $0.19. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.08. Heron Therapeutics had a negative return on equity of 56.85% and a negative net margin of 138.31%. The company had revenue of $25.40 million for the quarter, compared to the consensus estimate of $21.23 million. During the same quarter in the prior year, the company earned ($0.80) earnings per share. Heron Therapeutics’s revenue was down 19.6% on a year-over-year basis.

A number of research firms have weighed in on HRTX. Guggenheim began coverage on Heron Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $24.00 target price on the stock. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, April 15th. Stifel Nicolaus assumed coverage on Heron Therapeutics in a research note on Monday. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, Zacks Investment Research downgraded Heron Therapeutics from a “buy” rating to a “hold” rating and set a $18.00 price objective on the stock. in a research note on Wednesday, May 20th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $36.10.

HRTX stock traded up $0.46 during trading on Tuesday, reaching $14.71. The stock had a trading volume of 4,530,766 shares, compared to its average volume of 1,379,845. Heron Therapeutics has a 52 week low of $9.60 and a 52 week high of $26.81. The stock’s 50 day moving average is $18.34 and its two-hundred day moving average is $18.55. The company has a current ratio of 4.53, a quick ratio of 4.17 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.33 billion, a PE ratio of -6.48 and a beta of 1.55.

A number of institutional investors and hedge funds have recently modified their holdings of HRTX. Sowell Financial Services LLC raised its stake in Heron Therapeutics by 2,443.5% during the 1st quarter. Sowell Financial Services LLC now owns 2,340 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,248 shares during the period. PNC Financial Services Group Inc. raised its stake in Heron Therapeutics by 325.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,698 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 2,064 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in Heron Therapeutics by 259.7% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,579 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 1,862 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Heron Therapeutics by 82.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,896 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 4,463 shares during the period. Finally, X Square Capital LLC bought a new stake in Heron Therapeutics during the 1st quarter valued at approximately $117,000.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Story: What is the definition of market timing?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.